Area of research
Radiology, Nuclear Medicine and Imaging · Modeling and Simulation
Research interest
Research interests include Cancer research, Daratumumab, CD38, Immune system, Lenalidomide, and Multiple myeloma.
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects
Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide